^
EGFR exon 19 deletion + T790M + C797S + HER-2 amplification
LUAD
afatinib + rivoceranib
Sensitive
:
C4
Onco Targets Ther - 1d
EGFR T790M + C797S
LUAD
gefitinib + osimertinib
Resistant
:
C4
Onco Targets Ther - 1wk
EGFR T790M + C797S
LUAD
osimertinib + anlotinib
Sensitive
:
C4
Onco Targets Ther - 1wk
MET amplification
LUAD
crizotinib
Sensitive
:
C3
Tumori - 3wk
NCOR2-NTRK1 fusion + TMB-H
LUAD
camrelizumab
Resistant
:
C4
BMC Pulm Med - 3wk
NCOR2-NTRK1 fusion + TMB-H
LUAD
larotrectinib
Sensitive
:
C4
BMC Pulm Med - 3wk
No biomarker
LUAD
nintedanib
Sensitive
:
A1
PD-L1 underexpression
LUAD
nivolumab + ipilimumab
Sensitive
:
A2
EGFR mutation
LUAD
gefitinib
Sensitive
:
B
EGFR T790M
LUAD
erlotinib
Sensitive
:
B
EGFR exon 19 deletion
LUAD
gefitinib
Sensitive
:
B
EGFR mutation
LUAD
afatinib
Sensitive
:
B
EGFR exon 19 deletion
LUAD
afatinib
Sensitive
:
B
EGFR L858R
LUAD
gefitinib
Sensitive
:
B
EGFR L858R
LUAD
erlotinib
Resistant
:
B
EGFR T790M
LUAD
gefitinib
Sensitive
:
B
PD-L1 expression
LUAD
atezolizumab
Sensitive
:
C1
MET exon 14 mutation
LUAD
tepotinib
Sensitive
:
C1
EGFR exon 19 deletion
LUAD
osimertinib
Resistant
:
C1
BRAF V600E
LUAD
trametinib + dabrafenib
Sensitive
:
C1
ATM mutation
LUAD
olaparib
Sensitive
:
C1
EGFR T790M
LUAD
osimertinib
Resistant
:
C1
EGFR L858R
LUAD
osimertinib
Sensitive
:
C1
EGFR mutation
LUAD
erlotinib
Sensitive
:
C1
EGFR mutation
LUAD
bevacizumab
Sensitive
:
C2
KRAS mutation
LUAD
trametinib
Sensitive
:
C2
EGFR S768I
LUAD
erlotinib
Sensitive
:
C2
PD-L1 overexpression
LUAD
pembrolizumab
Sensitive
:
C2
EGFR mutation
LUAD
cetuximab + afatinib
Sensitive
:
C3
EGFR mutation + PD-L1 overexpression
LUAD
Tyrosine kinase inhibitor
Resistant
:
C3
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our